Clinical trials
Hematologic Diseases clinical trials
Below are recruiting hematologic diseases clinical trials, each written for real people, not researchers. We’re tracking 247 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07578675Recruiting
Brain Activity Patterns in Anemia Patients
This study uses a non-invasive brain imaging tool to understand how anemia affects thinking and brain function. Researchers hope to learn more about why some anemia patients experience cognitive problems and how to help them.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT07539662Enrolling by invitation
Cord Blood Stem Cell Transplant for ALS
This trial tests whether a transplant of special cells from donated umbilical cord blood can help slow or improve symptoms of ALS (amyotrophic lateral sclerosis, also called Lou Gehrig's disease). The cells may help repair nerve damage and reduce disease progression.
TianjinAges 35–50 - NCT07172191Enrolling by invitation
Fecal transplant for adults with blood cancer and infections
This trial tests whether transplanting healthy donor bacteria (fecal microbiota) into the gut can help adults with blood cancers who have stubborn infections, C. diff, or complications after stem cell transplant. It may reduce dangerous germs and improve gut health.
Budapest, BudapestAges Any age - NCT05046444Recruiting
Testing tricky blood cancer diagnoses with advanced DNA sequencing
This study uses advanced DNA sequencing to figure out unclear or unusual blood (hematologic) conditions when standard tests are not enough. It may help your care team reach a more accurate diagnosis by better understanding what’s driving your illness.
MunichAges 18–99 - NCT00920972RecruitingPhase 1/Phase 2
Bone marrow transplant prep for children with non-cancer blood disorders
This early-stage study tests a specific chemotherapy “conditioning” regimen to prepare the body for a bone marrow transplant in children with certain non-cancer blood or immune conditions. It may help the transplant work better, but it also carries risks from the chemotherapy and transplant process.
Phoenix, ArizonaAges Up to 20 years - NCT05443425RecruitingPhase 1
Leflunomide plus steroids for acute graft-versus-host disease
This early-phase trial tests whether adding leflunomide to standard steroid treatment can better control acute graft-versus-host disease (aGvHD) after a stem cell transplant. It may help reduce the immune reaction that damages the body while keeping treatment safe and manageable.
Duarte, CaliforniaAges 18 years+ - NCT05463796Recruiting
Prevention and early detection for people at high cancer risk
This study looks at surveillance (watching closely), prevention, and early “interception” steps to lower the chance that cancer will develop or be found later. It is for people with genetic risk, past cancer treatment exposures, strong family history, or certain early pre-cancer or high-risk conditions.
Boston, MassachusettsAges Any age - NCT05694806Recruiting
CT scan study for blood cancers with a chest mass syndrome
This study looks at how CT scan findings in the chest (mediastinum) can relate to outcomes for people with blood cancers who have mediastinal mass syndrome. It may help doctors better understand which scan features matter most when deciding care in the ICU.
ToulouseAges 16 years+ - NCT04466059Recruiting
AI tool for leukemia diagnosis using blood or marrow samples
This study tests whether an AI (computer system) can help improve leukemia and related blood cancer diagnoses. You may be able to help if your doctor is already evaluating you for a possible blood disorder and your sample is high enough quality for testing.
Munich, BavariaAges 18 years+ - NCT06690684Enrolling by invitation
Finding new blood markers for heart disease
This study is looking for people who have had a heart attack or have heart failure to discover new markers in your blood that could help doctors better understand and treat heart disease. By collecting samples and health data, researchers hope to find clues that improve care for future patients.
Shanghai, Jing 'an DistrictAges 30 years+ - NCT07359859RecruitingPhase 2
Ruxolitinib to prevent GVHD in stem cell transplant
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
Basking Ridge, New JerseyAges 18 years+ - NCT06416761Recruiting
Genetics and kidney disease progression study
This study looks at how genetics affect the progression of kidney diseases. Joining may help researchers understand your condition better and find better treatments.
MilanAges 18 years+ - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Birmingham, AlabamaAges 18–66 - NCT05889806Enrolling by invitation
Study uses blood and tissue samples for gene and protein testing
This study collects and analyzes your donated samples (like blood or other biospecimens) to look for patterns in genes and proteins. The results may help researchers understand disease biology and improve future tests or treatments.
New Orleans, LouisianaAges 18 years+ - NCT06689800Recruiting
Family communication tool for kids getting transplant or cell therapy
This study looks at a family communication tool for children and teens getting stem cell transplants or cellular therapy. It helps families talk about treatment together.
St Louis, MissouriAges 8 years+ - NCT06799195RecruitingPhase 2
Better GVHD prevention after stem cell transplant
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
Omaha, NebraskaAges 60 years+ - NCT07270263Recruiting
Lower-dose blood thinners for people with blood cancers
This trial compares lower doses of two common blood thinner pills (apixaban and rivaroxaban) to a daily injection (enoxaparin) to prevent blood clots in people receiving treatment for blood cancers like multiple myeloma, lymphoma, or certain other blood cancers.
Gdansk, Pomeranian VoivodeshipAges 18 years+ - NCT07047456RecruitingPhase 3
Stem cell infusion timing and graft-versus-host disease risk in blood cancer patients
This trial looks at whether the time when stem cells are infused affects the chance of developing graft-versus-host disease (aGVHD) after a cord blood transplant. It may help find the best timing to improve outcomes for people with blood cancers.
Hefei, AnhuiAges Any age - NCT05470491RecruitingPhase 1/Phase 2
Haploidentical bone marrow transplant with GVHD prevention drugs
This trial tests a reduced-intensity bone marrow transplant from a related donor (haploidentical), using medicines to help prevent a serious complication called GVHD. It is for people with certain blood cancers and aims to improve outcomes by balancing transplant benefit with lower treatment intensity.
Bethesda, MarylandAges 12–120 - NCT06718283Recruiting
A study of blood tests in young people with lupus
This study looks at blood test results in children and teenagers with lupus to see if they relate to how active the disease is or if it has caused long-term damage. It may help doctors better understand the disease.
SohagAges Up to 18 years - NCT03818334RecruitingPhase 2/Phase 3
Cyclophosphamide after transplant for blood cancer without sibling donor
This trial studies giving cyclophosphamide after a stem cell transplant when there is no matched sibling donor, but a well-matched unrelated donor is available. It aims to improve outcomes for people with blood cancers undergoing this transplant.
São Paulo, São PauloAges 1–75 - NCT04398628Recruiting
Study of non-cancer blood disorders in people with bleeding or clotting
This study follows people with inherited or acquired non-cancer blood disorders to better understand symptoms, causes, and how different treatments work over time. You may be placed into a disorder-specific group, depending on your diagnosis and testing results.
Phoenix, ArizonaAges Any age - NCT05573802RecruitingPhase 1/Phase 2
Belantamab and other medicines for new multiple myeloma
This early-phase study tests how safe and effective belantamab mafodotin is when combined with lenalidomide and dexamethasone, plus a medicine called nirogacestat, in people with newly diagnosed multiple myeloma who cannot have stem cell transplant. It may help shrink the cancer and improve outcomes, while doctors track side effects.
AthensAges 18 years+ - NCT07366801RecruitingPhase 2/Phase 3
Preventing graft versus host disease in children with blood cancer
This trial tests if adding special immune cells (Treg cells) to a stem cell transplant from a half-matched donor can lower the risk of graft versus host disease (a serious side effect where donor cells attack the patient's body) in children and young adults with blood cancers.
MoscowAges 1–25
Hear when a new Hematologic Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematologic diseases?
- Yes. Clin2 currently lists 247 recruiting hematologic diseases studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematologic diseases trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematologic diseases trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.